Dynamic Technology Lab Private Ltd Acquires Shares of 25,764 Prothena Co. plc (NASDAQ:PRTA)

Dynamic Technology Lab Private Ltd acquired a new stake in Prothena Co. plc (NASDAQ:PRTA) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 25,764 shares of the biotechnology company’s stock, valued at approximately $432,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Prothena by 5.1% in the 1st quarter. Vanguard Group Inc. now owns 1,125,283 shares of the biotechnology company’s stock valued at $27,873,000 after buying an additional 54,728 shares in the last quarter. Armistice Capital LLC raised its position in shares of Prothena by 42.3% in the 2nd quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company’s stock valued at $32,198,000 after buying an additional 464,000 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Prothena by 226.4% in the 2nd quarter. SG Americas Securities LLC now owns 54,572 shares of the biotechnology company’s stock valued at $1,126,000 after buying an additional 37,852 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Prothena in the 2nd quarter valued at approximately $905,000. Finally, Duncan Williams Asset Management LLC acquired a new position in shares of Prothena in the 3rd quarter valued at approximately $816,000. Institutional investors own 97.08% of the company’s stock.

Prothena Price Performance

PRTA opened at $16.21 on Friday. Prothena Co. plc has a fifty-two week low of $13.22 and a fifty-two week high of $41.54. The firm has a market capitalization of $872.24 million, a price-to-earnings ratio of -6.54 and a beta of 0.16. The company’s 50 day moving average price is $17.02 and its two-hundred day moving average price is $19.87.

Prothena (NASDAQ:PRTA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $1.22 million. During the same period in the previous year, the firm posted $0.38 EPS. The company’s revenue for the quarter was down 98.9% compared to the same quarter last year. As a group, equities research analysts predict that Prothena Co. plc will post -2.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Oppenheimer dropped their target price on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Bank of America lowered their price objective on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating for the company in a research report on Tuesday, October 1st. Royal Bank of Canada lowered their price objective on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and set a $84.00 price objective on shares of Prothena in a research report on Wednesday, November 13th. Finally, StockNews.com cut shares of Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.86.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.